Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant.
Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.
['Broglie|Larisa|L|', 'Helenowski|Irene|I|', 'Jennings|Lawrence J|LJ|', 'Schafernak|Kristian|K|', 'Duerst|Reggie|R|', 'Schneiderman|Jennifer|J|', 'Tse|William|W|', 'Kletzel|Morris|M|', 'Chaudhury|Sonali|S|']
D000293:Adolescent D002648:Child D002675:Child, Preschool D046528:Chimerism D005260:Female D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D007223:Infant D015470:Leukemia, Myeloid, Acute D008297:Male D009190:Myelodysplastic Syndromes D009364:Neoplasm Recurrence, Local D012189:Retrospective Studies D013601:T-Lymphocytes D018183:Transplantation Chimera D055815:Young Adult
chimerism pediatrics AML relapse HCT